April 4 (Reuters) - BIOFRONTERA AG B8FGn.DE :
* PRELIMINARY FY TOTAL REVENUE DECREASED 5% TO EUR 28.8
MILLION,
COMPARED TO EUR 30.3 MILLION IN 2020
* PRELIM FY PRO-FORMA EBITDA AND EBIT FOR 2021 ADJUSTED FOR
ONE-TIME EFFECTS ARE BOTH WITHIN GUIDANCE OF EUR -11 TO -14
MILLION FOR EBITDA AND EUR -13 TO -16 MILLION FOR EBIT
* HAD A CASH POSITION OF EUR 6.9 MILLION AS OF DECEMBER 31,
2021,
COMPARED TO EUR 16.5 MILLION AS OF DECEMBER 31, 2020
* ANTICIPATES TO GENERATE SALES BETWEEN EUR 24 MILLION AND
EUR 27
MILLION FOR 2022 FISCAL YEAR
* EXPECTS EBITDA TO BE CLOSE TO BREAK-EVEN IN 2022 AND A
NEGATIVE
EBIT IN LOW SINGLE-DIGIT MILLION RANGE
* IF MARKETS CONTINUE TO RECOVER, COMPANY EXPECTS INCREASING
REVENUES AS WELL AS POSITIVE EBITDA AND EBIT FROM 2023 ONWARDS
Source text for Eikon: ID:nPex7lvdsa
Further company coverage: B8FGn.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))